Sara Soudi

Sara Soudi

Auto-generated profile, based on publicly available information

Sara Soudi

Department of Immunology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2010 in International Immunopharmacology
Verified
Journal Article
Closed access
ZGZahra Golzari
Zahra Golzari
FSFatemeh Shabkhiz
Fatemeh Shabkhiz
SSSara Soudi
Sara Soudi
MKMohammad Reza Kordi
Mohammad Reza Kordi
SHSeyed Mahmoud Hashemi
Seyed Mahmoud Hashemi

27 January 2023 in Journal of Controlled Release
Verified
Journal Article
Closed access
KMKosar Malekpour
Kosar Malekpour
AHAli Hazrati
Ali Hazrati
SSSara Soudi
Sara Soudi
SHSeyed Mahmoud Hashemi
Seyed Mahmoud Hashemi

1 November 2013 in International Immunopharmacology
Verified
Journal Article
Closed access
FYForouzan Yousefi
Forouzan Yousefi
MEMasoumeh Ebtekar
Masoumeh Ebtekar
MSMasoud Soleimani
Masoud Soleimani
SSSara Soudi
Sara Soudi
SHSeyed Mahmoud Hashemi
Seyed Mahmoud Hashemi

1 November 2022 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
AHAli Hazrati
Ali Hazrati
KMKosar Malekpour
Kosar Malekpour
SSSara Soudi
Sara Soudi
SHSeyed Mahmoud Hashemi
Seyed Mahmoud Hashemi
Cell therapy is one of the newest therapeutic approaches for treating tissue destruction diseases and replacing damaged parts in defective tissues. Among different cells, mesenchymal stem cells (MSCs) have received a lot of attention due to their advantages and desirable properties. Also, MSCs-derived secretome, which includes various growth factors, cytokines, and extracellular vesicles (EVs), is used in the treatment of different types of diseases. However, the application of MSCs in an intact form brings their functionality with limitations. For this reason, different methods are recommended to increase their efficiency and the extracellular vesicles derived from them. One of these methods is gene editing of these cells. Among the different techniques for MSCs gene editing, CRISPR/Cas9 can increase the therapeutic potential of MSCs in a targeted manner due to its advantages. In order to achieve the desired result, various genes have been manipulated in MSCs, including genes involved in stemness, aging, migration, proliferation, survival, and inflammatory responses. Engineering MSCs with this method affects the cells' characteristics, changes their cytokine and different growth factors secretions, and increases their therapeutic efficiency.

18 December 2008 in Cells Tissues Organs
Verified
Journal Article
Closed access
SHSeyed Mahmoud Hashemi
Seyed Mahmoud Hashemi
MSMasoud Soleimani
Masoud Soleimani
SZSeyed Shahrooz Zargarian
Seyed Shahrooz Zargarian
VHVahid Haddadi-Asl
Vahid Haddadi-Asl
NANaser Ahmadbeigi
Naser Ahmadbeigi
Yousef MohammadiYousef Mohammadi
Yousef Mohammadi
Tissue engineering of implantable cellular constructs is an emerging cellular therapy for hepatic disease. In this study, we tested the ability of poly(ε-caprolactone) (PCL) nanofiber scaffold to support and maintain hepatic differentiation of human cord blood-derived unrestricted somatic stem cells (USSCs) in vitro. USSCs, self-renewing pluripotent cells, were isolated from human cord blood. The electrospun PCL nanofiber porous scaffold was constructed of uniform, randomly oriented nanofibers. USSCs were seeded onto PCL nanofiber scaffolds, and were induced to differentiate into hepatogenic lineages by culturing with differentiation factors for 6 weeks. RT-PCR analysis of endoderm and hepatic-specific gene expression, immunohistochemical detection of cytokeratin 18 (CK-18), α-fetoprotein, albumin, glycogen storage and indocyanine green uptake confirmed the differentiation of USSCs into endoderm and hepatocyte-like cells. In the present study, we show that hepatocyte-like cells differentiated from USSCs on the PCL nanofiber scaffold can be candidate for tissue engineering and cell therapy of hepatic tissues.

1 January 2021 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
PDF file
FTFataneh Tavasolian
Fataneh Tavasolian
AHAhmad Zavaran Hosseini
Ahmad Zavaran Hosseini
MRMohsen Rashidi
Mohsen Rashidi
SSSara Soudi
Sara Soudi
EAElham Abdollahi
Elham Abdollahi
Amirhossein SahebkarAmirhossein Sahebkar
Amirhossein Sahebkar
Exosomes are small extracellular vesicles that pass genetic material between various cells to modulate or alter their biological function. The role of exosomes is to communicate with the target cell for cell-to-cell communication. Their inherent characteristics of exosomes, such as adhesion molecules, allow targeting specifically to the receiving cell. Exosomes are involved in cell to cell communication in the immune system including antigen presentation, natural killer cells (NK cells) and T cell activation/polarisation, immune suppression and various anti-inflammatory processes. In this review, we have described various functions of exosomes secreted by the immune cells in initiating, activating and modulating immune responses; and highlight the distinct roles of exosomal surface proteins and exosomal cargo. Potential applications of exosomes such as distribution vehicles for immunotherapy are also discussed.